nach oben

Erschienen in:

01.03.2011 | Gynecologic Oncology

Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study

verfasst von: E. A. Fayallah, Reda A. Hemida, A. M. Gamal, E. Abd Elhady, K. I. Anwar, N. A. Nada, L. S. Sherif, M. T. Sayed-Ahmed

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To study the value of pretreatment testing of P53 overexpression in selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma.

Patients and methods

This prospective randomized clinical study included 38 patients with histologically confirmed endometrial carcinoma and staged clinically as stage I. Immunohistochemical staining of the tumor specimens obtained by dilatation and curettage with P53 monoclonal antibodies was done. The patients were randomized into two groups according to the planned surgical treatment: hysterectomy group and hysterectomy plus pelvic lymphadenectomy group.

Results

There was no significant difference in mean age, parity, medical status, surgical stage, histologic types, grade of differentiation, and myometrial invasion between the two groups. The survival rate in the hysterectomy group in our study was 82.4% and the recurrence rate was 17.6%, while in hysterectomy and lymphadenectomy group the survival rate was 81.0% and the recurrence rate was 19%. Adding pelvic lymphadenectomy was found to be associated with prolonged recurrence time in the P53-positive patients (24.07 vs. 17.8 months for group A).

Conclusion

Pretreatment testing of P53 expression is recommended to help with other prognostic factors in the selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma.

HO TH, Chee JJ, Tay EH, Low JH, Yan KL (2003) Endometrial adenocarcinoma of the uterus: surgicopathological correlation and the role of pelvic lymphadenectomy. Ann Acad Med Singap 32:670–675PubMed

Ceccaroni M, Savelli L, Bovicclli A, Alboni C, Ceccarini M, Farina A, Bovicelli L (2004) Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anti Cancer Res 24(3):2073–2078

Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA et al (2008) Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol 198:457.e1–457.e6CrossRef

Papanikolaou AI, Goutzioulis M, Misailidou D, Vergot I, Makedos G (2006) Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 274:91–96CrossRefPubMed

Mano Y, Kikushi Yamamoto K, Kita T, Hirata J, Tode T (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35:1214–1219

Mariani A, Sebo TJ, Katzmann JA, Rocke PC, Koeney CL, Lesnick TG, Podratz KC (2005) Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol 96(3):594–600CrossRefPubMed

Osmangaolu MA, Kadiglu S, Bozkaya H (2005) The relationship between mutant P53 gene, DNA contents and conventional clinico-pathological prognostic variable in cases with endometrial carcinoma. Eur J. Gynecol Oncol 26(1):64–70

Jamel A, Thomas A, Murray t (2002) Cancer statistics. Cancer J Clin 52:23–57CrossRef

Kohler MF, Creasman UT (2008) Controversies surrounding lymphadenectomy and post operative radiotherapy in the treatment of endometrial carcinoma. Future Oncol 4(3):379–387CrossRefPubMed

10.

Benshacker I, Pavelka J, Cohn DE (2005) Surgical staging for patients presenting with G1 endometrial carcinoma. Obstet Gynecol 97(2):105–487

11.

ASTEC Study Group, Kitchener H, Swart AM, Quin Q, Amos C, Pamar MK (2009) Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial); a randomized study. Lancet 2–10:373 (9658):125–36

12.

Creasman WT, De Geest K, Disaia PJ, Zaino RJ (1999) Significance of true surgical pathologic staging. A Gynecologic Oncology Group Study. Am J Obstet Gynecol 181:31–34CrossRefPubMed

13.

Pilka R, Mickova I, Lubusky M, Duskova M, Ricankova M, Kudela M (2008) Expression of P53, Ki 67, bcl-2, C-erb 2, estrogen and progesterone receptors in endometrial cancer. Ceska Gynekol 73(4):222–227PubMed

14.

Simionescu C, Georgescu CV, Magaritescu C, Bata S, Marinescu M, Enachescu V, Patnu E (2006) P53 and PCNA immunoexpression in endometrial carcinomas; Rom. J. Morphol. Embryol. 97(2):137–141

15.

Appel ML, Edelweiss MI, Flek J, Rivore WA, Monego HI, Dos Reis R (2008) P53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathol. Oncol. Res. 14(1):23–30CrossRefPubMed

16.

Veralucia LB, Liliana AL (2003) P53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy. Sao Paulo Med. J 12(4):163–166

17.

Nicola R, Simone F, Federico P, Barbara M, Franco G, Marina G, Ezio F (2005) The association between P53 expression, stage and histological feature in endometrial cancer. Eur. J. Obstet Gynecol 123(1):111–116CrossRef

18.

Marcia LM, Appel Maria I, Edelweiss MI, James F, Luis F, Heleusa I, Ricordo R (2008) P53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathol. Oncol. Res 14:23–30CrossRef

19.

Erkanli S, Eren F, Pekin S, Bagis T (2004) Bcl-2 and P53 expression in endometrial carcinoma. J Exp Clin Cancer Res 23(1):97–103PubMed

20.

Cerchi PL, Marras V, Capobianco G, Amborosini G, Piga MD, Fadda GM, Rosas N, Dessole S (2001) Prognostic value of P53, C-erb-B2 and MIB-1 in endometrial carcinoma. Eur. J. Gynecol Oncol 22(6):451–453

21.

Benedette Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangilli G, Katsaros D, Garrozzo G, Cammpagnano M, Dondello N, Greggi S, Melpignano M, Raspagliesi F, Ragnini Comio G. Grassi R, Franchi M, Giannarelle D (2008) Systemic pelvic lymphadenectomy versus no lymphadenectomy in early stage endometrial cancer: a randomized clinical trial. J Nat Cancer Inst 100(23):1707–1716

22.

Kilogore LC, Partridge EE, Awarez RD, Austin JM, Shingleton HM, Noojin F (1995) Adenocarcinoma of the endometrium. Survival comparisons with and without pelvic node sampling. Gynecol Oncol 56:29–33CrossRef

23.

Huh WK, Cohen DE, Fowbr JM, Straughn JM (2007) Cost effective analysis of strategies for surgical management of grade I endometrial adenocarcinoma. Obstet Gynecol 109(6):1388–1395CrossRefPubMed

24.

Crugan JM, Havrilesky LJ, Calingarts B, Synan J, Secord AA, Sopre JT (2005) Retrospective analysis of selective lymphadenectomy in apparent early stage endometrial cancer. J Clin Oncol 23(16):3668–3675

25.

Byrd LM, Swindell R, Webber-Rookes D, Hannan R, Hunter RD, Lisey J, Davidson SE (2008) Endometrial adenocarcinoma: an analysis of treatment and outcome. Oncol Rep 20(5):1221–1228PubMed

26.

Larson DM, Broste SK, Krawisz BR (1998) Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 91:355CrossRefPubMed

27.

Franchi M, Chezzi F, Riva C, Miglier M, Butterlli M (2001) Post operative complications after pelvic lymphadenectomy for surgical staging endometrial carcinoma. J Surg Oncol 78(4):232–237CrossRefPubMed

28.

Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y (2006) Risk factors for early late post operative complications of patients with endometrial carcinoma. Eur J Obstet Gynecol 65:251

Titel: Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study
verfasst von: E. A. Fayallah
Reda A. Hemida
A. M. Gamal
E. Abd Elhady
K. I. Anwar
N. A. Nada
L. S. Sherif
M. T. Sayed-Ahmed
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1468-3

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study